Diagnostic Performance of Serum Biglycan for Prostate Cancer Detection in Men With PSA Levels of 4-10 ng/mL
Objective: In men whose prostate-specific antigen (PSA) values fall within the diagnostic gray zone, specificity for prostate cancer is poor, frequently resulting in unnecessary biopsies. Biglycan, a small leucine-rich proteoglycan associated with tumor progression, has not been well characterized as a circulating biomarker in this setting. We investigated whether serum biglycan could add diagnostic value beyond PSA-based parameters in prostate cancer detection. Methods: We prospectively enrolled 115 men undergoing a standard 12-core transrectal ultrasound-guided biopsy for a PSA value between 4 and 10 ng/mL. Based on histopathological outcome, participants were grouped as benign prostatic hyperplasia (BPH) or prostate cancer. Serum biglycan was quantified by enzyme-linked immunosorbent assay and analyzed alongside age, total and free PSA, free/total PSA ratio, prostate volume, and ISUP grade. Predictors of malignancy were identified through logistic regression, and diagnostic accuracy was assessed via receiver operating characteristic (ROC) curves. Results: Of 115 participants, 62 had BPH and 53 had prostate cancer. Biglycan was markedly elevated in the cancer group, and multivariable analysis identified it as the sole independent predictor of malignancy and its inclusion improved discrimination beyond conventional clinical parameters. ROC analysis showed an area under the curve of 0.790 for biglycan, which was higher than those of total PSA and the free/total PSA ratio. Adding biglycan to the clinical model increased the AUC from 0.662 to 0.814, with optimism-corrected AUCs increasing from 0.613 to 0.781. At a Youden-derived threshold of 6.63 ng/mL, biglycan achieved 86.8% sensitivity, 62.9% specificity, 66.7% positive predictive value, and 84.8% negative predictive value. Levels were further elevated among men with clinically significant disease. These findings support further evaluation of serum biglycan as a complementary biomarker in the PSA gray zone, although external validation is required before clinical implementation.
Authors
- Emin Taha Keskin (ORCID: https://orcid.org/0000-0002-1222-6424)
- Oğuzhan AKPINAR (ORCID: https://orcid.org/0000-0003-3492-8467)
- Yunus Çolakoğlu (ORCID: https://orcid.org/0000-0001-6432-765X)
- Soner Çoban (ORCID: https://orcid.org/0000-0002-4687-8754)
- Batu Akalin (ORCID: https://orcid.org/0000-0001-7570-1862)
- Enes Yavuz (ORCID: https://orcid.org/0000-0002-8494-6375)
- Abdulmuttalip Simsek
Publication Details
- Journal
- Urologia Internationalis
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1159/uin/aewag063
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00